{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+every+2+weeks",
    "query": {
      "intervention": "Placebo every 2 weeks"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1488,
    "total_pages": 149,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+every+2+weeks&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T11:07:29.340Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05831241",
      "title": "Effects of Ashwagandha Extract (Capsule KSM-66 300 mg) on Sexual Health in Healthy Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sexual Health"
      ],
      "interventions": [
        {
          "name": "Ashwagandha",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "SF Research Institute, Inc.",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2023-07-12",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05831241"
    },
    {
      "nct_id": "NCT00280566",
      "title": "Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Mania",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 584,
      "start_date": "2005-12",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00280566"
    },
    {
      "nct_id": "NCT04134728",
      "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sarilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to GSK3196165/ Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2019-10-31",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 46,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134728"
    },
    {
      "nct_id": "NCT03589885",
      "title": "Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo 2 mL auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Placebo 1 mL prefilled syringe",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 2 mL auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 1 mL prefilled syringe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2018-12-19",
      "completion_date": "2020-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Saint Joseph",
          "state": "Missouri"
        },
        {
          "city": "Verona",
          "state": "New Jersey"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589885"
    },
    {
      "nct_id": "NCT00754052",
      "title": "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Down Syndrome",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Aricept (donepezil hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "11 Years to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-09",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-23",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Herndon, Virginia",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Herndon",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754052"
    },
    {
      "nct_id": "NCT00675714",
      "title": "Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Stable Isotope Infusion Study",
          "type": "PROCEDURE"
        },
        {
          "name": "Collection of blood and tissues",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Humatrope",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Oxandrolone",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Oxandrolone and propranolol combined",
          "type": "DRUG"
        },
        {
          "name": "Humatrope and propranolol combined",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Exercise--Hospital supervised intensive exercise program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Home exercise program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "Up to 80 Years"
      },
      "enrollment_count": 1126,
      "start_date": "2004-01",
      "completion_date": "2019-07-15",
      "has_results": false,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675714"
    },
    {
      "nct_id": "NCT06981078",
      "title": "A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Verekitug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Upstream Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 666,
      "start_date": "2025-07-02",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 29,
      "location_summary": "Bakersfield, California • Encino, California • Lomita, California + 23 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06981078"
    },
    {
      "nct_id": "NCT03615326",
      "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Neoplasms",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "S-1",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 738,
      "start_date": "2018-10-05",
      "completion_date": "2025-11-12",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615326"
    },
    {
      "nct_id": "NCT03325010",
      "title": "Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "Valbenazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 127,
      "start_date": "2017-10-05",
      "completion_date": "2018-11-16",
      "has_results": true,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 34,
      "location_summary": "Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Clarita",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03325010"
    },
    {
      "nct_id": "NCT06282159",
      "title": "A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myasthenia Gravis, Generalized"
      ],
      "interventions": [
        {
          "name": "Claseprubart",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dianthus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2024-02-23",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-08T11:07:29.340Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06282159"
    }
  ]
}